Newsfile
March 12, 2026 5:58AM GMT
Dublin, Ireland--(Newsfile Corp. - March 12, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the convening of its upcoming Ordinary Annual General Meeting of Shareholders (AGM) to be held on 10 April 2026 in Amsterdam.
The agenda includes, among others, the following discussion and voting items:
The convening notice with the complete AGM agenda items, the explanatory notes and the written proxy are all available on the Company’s website via www.cosmohealthconfidence.com/agm. Cosmo’s Annual Report 2025 and ESG Report 2025 can be found here: www.cosmohealthconfidence.com/key-financial-reports.
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit www.cosmohealthconfidence.com.
For further information regarding the AGM 2026, please contact:
generalmeeting@cosmohc.com
Attachments
PDF - English
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288242